Erytech Pharma S.A. (ERYP): Price and Financial Metrics
GET POWR RATINGS... FREE!
ERYP Stock Summary
- ERYTECH PHARMA SA's market capitalization of $18,704,187 is ahead of only 6.53% of US-listed equities.
- Revenue growth over the past 12 months for ERYTECH PHARMA SA comes in at 448.59%, a number that bests 97.76% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ERYP comes in at -69.85% -- higher than that of only 8.1% of stocks in our set.
- Stocks that are quantitatively similar to ERYP, based on their financial statements, market capitalization, and price volatility, are IPSC, HYLN, DBVT, HCM, and CANF.
- Visit ERYP's SEC page to see the company's official filings. To visit the company's web site, go to www.erytech.com.
ERYP Stock Price Chart Interactive Chart >
ERYP Price/Volume Stats
|Current price||$0.60||52-week high||$2.99|
|Prev. close||$0.61||52-week low||$0.50|
|Day high||$0.60||Avg. volume||272,686|
|50-day MA||$0.64||Dividend yield||N/A|
|200-day MA||$1.11||Market Cap||18.61M|
Erytech Pharma S.A. (ERYP) Company Bio
ERYTECH Pharma Société Anonyme, a clinical-stage biopharmaceutical company, develops therapies for rare forms of cancer and orphan diseases in France and internationally. The company is developing a pipeline of product candidates targeting markets with unmet medical need using its proprietary ERYCAPS platform, a technology to encapsulate therapeutic drug substances inside red blood cells. It primarily focuses on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. The company was founded in 2004 and is based in Lyon, France.
Most Popular Stories View All
ERYP Latest News Stream
|Loading, please wait...|
ERYP Latest Social Stream
View Full ERYP Social Stream
Latest ERYP News From Around the Web
Below are the latest news stories about ERYTECH PHARMA SA that investors may wish to consider to help them evaluate ERYP as an investment opportunity.
ERYTECH Announces Receipt of Nasdaq Notice Cambridge, MA (U.S.) and Lyon (France), October 13, 2022 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC ("Nasdaq") dated October 7, 2022, indicating that, based upon a closing bid price of less than $1.00 per
Erytech Pharma SA Sponsored ADR (ERYP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022
Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net
ERYTECH Pharma S.A. (NASDAQ:NASDAQ:ERYP) Q2 2022 Results Conference Call September 13, 2022 08:30 AM ET Company Participants Gil Beyen - Chief Executive Officer Eric Soyer - Chief Financial…
Erytech Pharma press release (ERYP): 1H Net loss was €1M, a €27M improvement over the same period of last year.As of June 30, 2022, ERYTECH had cash and cash equivalents totaling…
ERYP Price Returns